BioNTech (BNTX) Stock Forecast & Price Target

BioNTech
Bear Case

Investors should be bearish about investing in BioNTech SE for these reasons:

• The company is currently unprofitable, as evidenced by a negative price-to-earnings ratio of -12.73 and a loss per share of -2.257 in the most recent reported quarter. This indicates that BioNTech SE is spending more than it is earning, which can be a concern for investors who prioritize immediate profitability and cash flow generation over long-term growth potential.
• CEO Ugur Sahin has been selling a significant number of shares, including a recent transaction on October 9, 2026, where he sold 36,209 shares. While insider selling can be due to personal financial needs, a consistent pattern of selling by a top executive may signal a lack of confidence in the stock's near-term performance or a desire to diversify personal holdings, which can be interpreted negatively by the market.
• Several major investment banks, including HC Wainwright, UBS Group, and Morgan Stanley, have recently lowered their price targets for the stock in late 2026. For example, HC Wainwright cut its target from $130.00 to $110.00, and Morgan Stanley reduced its target from $114.00 to $106.00. These downward revisions suggest that analysts are becoming more cautious about the company's future earnings potential and may be factoring in higher risks or slower growth expectations.
• The stock has experienced a decline in short interest, with the number of shares shorted dropping from 4,462,537 in February 2026 to 2,245,589 in October 2026. While a decrease in short interest can sometimes be positive, it may also indicate that short sellers are closing their positions due to a lack of conviction in the stock's downside potential, which could reduce the potential for a short squeeze and limit upward price momentum.
• The company's revenue has shown signs of weakness, with a year-over-year revenue growth of -35.4% reported in the most recent quarter. This significant decline in revenue suggests that BioNTech SE may be struggling to maintain its sales momentum, which could be a red flag for investors who are concerned about the company's ability to generate consistent income and sustain its operations in the long term.